Literature DB >> 6357432

Mutagenicity of the enantiomers of the diastereomeric bay-region benz(a)anthracene 3,4-diol-1,2-epoxides in bacterial and mammalian cells.

A W Wood, R L Chang, W Levin, H Yagi, D R Thakker, P J van Bladeren, D M Jerina, A H Conney.   

Abstract

Enantiomers of the diastereomeric pair of bay-region benz(a)anthracene 3,4-diol-1,2-epoxides in which the benzylic 4-hydroxyl group and epoxide oxygen are either cis (isomer 1) or trans (isomer 2) were evaluated for mutagenic activity in two histidine-dependent strains of Salmonella typhimurium, as well as in an 8-azaguanine-sensitive Chinese hamster cell line. In strain TA 98 of S. typhimurium, the diol-epoxide with (1S,2R,3R,4S) absolute configuration [(-)-diol-epoxide 2] was the most active isomer, although there was less than a 3-fold difference in the mutagenicity of the four diol-epoxides. However, in strain TA 100 of S. typhimurium, the enantiomeric diol-epoxide with (1R,2S,3S,4R) absolute configuration [(+)-diol-epoxide 2] was the most active diol-epoxide, and the two isomers with (3S,4R) absolute configuration [(-)-diol-epoxide 1 and (+)-diol-epoxide 2] were three to eight times more active than were the two isomers with (3R,4S) configuration. The highest degree of sensitivity to absolute configuration was observed in Chinese hamster V79 cells, in which the (1R,2S,3S,4R) isomer [(+)-diol-epoxide 2] was from three to 20 times more mutagenic than were the other three isomers. This metabolically predominant (+)-diol-epoxide 2 isomer, which has high activity in strain TA 100 of S. typhimurium and the Chinese hamster V79 cells, has the same absolute configuration as do the bay-region diol-epoxide isomers of benzo(a)pyrene and chrysene that have been shown previously to be exceptionally mutagenic to mammalian cells and highly tumorigenic in mice. Analysis of the mutagenic activity of the (+)- and (-)-isomers of the 1,2- and 3,4-tetrahydroepoxides of benz(a)anthracene revealed only small enantiomeric differences in strain TA 98 of S. typhimurium (2.5 fold) and little, if any, differences (less than 1.5-fold) in the other two mutagenicity systems. However, the extent to which the four tetrahydroepoxides were converted to nonmutagenic products by homogeneous microsomal epoxide hydrolase (EC 3.3.2.3) indicated marked differences in the stereoselectivity of the enzyme. (-)-(3R,4S)-Epoxy-1,2,3,4-tetrahydrobenz(a)anthracene appears to be an exceptionally good substrate for epoxide hydrolase.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6357432

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Mutagenicity and tumorigenicity of the four enantiopure bay-region 3,4-diol-1,2-epoxide isomers of dibenz[a,h]anthracene.

Authors:  Richard L Chang; Alexander W Wood; Mou Tuan Huang; Jian Guo Xie; Xiao Xing Cui; Kenneth R Reuhl; D R Boyd; Yong Lin; Weichung Joe Shih; Suresh K Balani; Haruhiko Yagi; Donald M Jerina; Allan H Conney
Journal:  Carcinogenesis       Date:  2013-05-13       Impact factor: 4.944

2.  Fungal metabolism and detoxification of polycyclic aromatic hydrocarbons.

Authors:  C E Cerniglia; G L White; R H Heflich
Journal:  Arch Microbiol       Date:  1985-11       Impact factor: 2.552

Review 3.  Conformational analysis of environmental agents: use of X-ray crystallographic data to determine molecular reactivity.

Authors:  V Cody
Journal:  Environ Health Perspect       Date:  1985-09       Impact factor: 9.031

Review 4.  The role of individual susceptibility in cancer burden related to environmental exposure.

Authors:  H Bartsch; E Hietanen
Journal:  Environ Health Perspect       Date:  1996-05       Impact factor: 9.031

5.  Genetic enhancement of microsomal epoxide hydrolase improves metabolic detoxification but impairs cerebral blood flow regulation.

Authors:  Anne Marowsky; Karen Haenel; Ernesto Bockamp; Rosario Heck; Sibylle Rutishauser; Nandkishor Mule; Diana Kindler; Markus Rudin; Michael Arand
Journal:  Arch Toxicol       Date:  2016-02-02       Impact factor: 5.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.